EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

Tatiana Kekeeva, Yulia Andreeva, Alexander Tanas iD, Alexey Kalinkin iD, Svetlana Khokhlova, Tatiana Tikhomirova, Alexandra Tyulyandina, Anatoly Popov iD, Maria Kuzmenko, Mikhail Volkonsky, Natalia Chernorubashkina, Valeria Saevets und 6 weitere

International Journal of Molecular Sciences · 22.06.2023 · 24 (13) · 10497

DOI: 10.3390/ijms241310497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.06.2023. Verfasst von Tatiana Kekeeva und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia. Hauptthemen laut MEDLINE: BRCA1 Protein, Ovarian Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the BRCA status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The BRCA mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic BRCA alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinOvarian NeoplasmsFemaleHumansMutationBRCA2 ProteinRussiaHomologous Recombination

Stichwörter der Autor:innen

BRCA mutationgenomic instability scorehomologous recombination deficiencypathological responsetumor purity

Substanzen

BRCA1 ProteinBRCA2 Protein

Autor:innen und Institutionen

  • Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia.
  • Department of Pathology, Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.
  • Oncological Department of Medical Treatment, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after V. I. Kulakov, 117997 Moscow, Russia.
  • N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russia.
  • National Medical Research Center of Surgery Named after A. Vishnevsky, Department of Antitumor Drug Therapy, 117997 Moscow, Russia.
  • Department of Oncology, Radiology and Radiotherapy, Tyumen State Medical University, 625023 Tyumen, Russia.

ORCID-Profile: Alexander Tanas, Alexey Kalinkin, Anatoly Popov, Vladimir Strelnikov

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Kekeeva, T., Andreeva, Y., Tanas, A., Kalinkin, A., Khokhlova, S., Tikhomirova, T., Tyulyandina, A., Popov, A., Kuzmenko, M., Volkonsky, M., Chernorubashkina, N., Saevets, V., Dmitriev, V., Nechushkina, V., Vedrova, O., Andreev, S., Kutsev, S., & Strelnikov, V. (2023). HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?. International Journal of Molecular Sciences, 24(13), 10497. https://doi.org/10.3390/ijms241310497

Vancouver

Kekeeva T, Andreeva Y, Tanas A, Kalinkin A, Khokhlova S, Tikhomirova T, et al. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?. International Journal of Molecular Sciences. 2023;24(13):10497. doi:10.3390/ijms241310497

BibTeX
@article{Kekeeva2023,
  author = {Kekeeva, Tatiana and Andreeva, Yulia and Tanas, Alexander and Kalinkin, Alexey and Khokhlova, Svetlana and Tikhomirova, Tatiana and Tyulyandina, Alexandra and Popov, Anatoly and Kuzmenko, Maria and Volkonsky, Mikhail and Chernorubashkina, Natalia and Saevets, Valeria and Dmitriev, Vadim and Nechushkina, Valentina and Vedrova, Olga and Andreev, Sergei and Kutsev, Sergey and Strelnikov, Vladimir},
  title = {HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {13},
  pages = {10497},
  doi = {10.3390/ijms241310497}
}
Kostenlos starten →